Top Story

FDA approves new clinical targets for Luminex xTAG GI pathogen panel

October 1, 2014

Luminex has received FDA approval to add three new targets to its xTAG Gastrointestinal Pathogen Panel, including adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae, according to a company press release.

The panel also has been cleared for use with specimens in the commonly used Cary-Blair transport medium.

Meeting News Coverage

Thrombocytopenia common among Romanian patients with HCV

October 1, 2014
NEW YORK — Thrombocytopenia had a high prevalence among Romanian patients with chronic hepatitis C virus infection, according to data presented at the AASLD/EASL…
In the Journals

Rapid response, inspector experience critical in E. coli outbreaks in UK

October 1, 2014
A review of Escherichia coli O157 outbreaks in the United Kingdom from the 1980s to 2013 highlighted two key lessons: Rapid response to an outbreak is crucial, and…
In the Journals

MERS fatality rates highest among men

October 1, 2014
The recent epidemic of Middle East respiratory syndrome coronavirus in Saudi Arabia had high fatality rates, especially among men, according to the results of an…
More News Headlines »
CME
figure

Pediatric Perspectives on the Management of Diarrhea in Infants and Children - Monograph

This activity is supported by an educational grant from Lupin Pharmaceuticals, Inc.

An estimated 1.2 million cases of giardiasis and 750,000 cases of cryptosporidiosis occur in the United States…
More »
Meeting News Coverage Video
figure

Robust antibiotic pipeline may require new thinking

September 20, 2014
WASHINGTON, D.C. — ICAAC 2014 keynote speaker John H. Rex, MD, senior vice president and head of infection…
More »
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »